Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 5/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | PDE5A | O76074 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.49 |
| ▸ | FSCN1 | Q16658 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | UBE2N | P61088 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2312640 | 0.85 | SCD (0.63) | SCDSMN1; SMN2MAPK1PDE5AHDAC6 | |
| SCHEMBL1500346 | 0.84 | GRK2 (0.60) | SMN1; SMN2PDE5AHDAC6LMNAHDAC3 | |
| SCHEMBL14048851 | 0.83 | SCD (0.60) | SCDSMN1; SMN2MAPK1FSCN1HTT | |
| SCHEMBL2314932 | 0.82 | SCD (0.66) | SCDSMN1; SMN2MAPK1PDE5AHDAC6 | |
| SCHEMBL3085533 | 0.81 | MMP13 (0.55) | PDE5AHDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL2312966 | 0.81 | SCD (0.59) | SCDSMN1; SMN2MAPK1LMNAHTT | |
| SCHEMBL2313385 | 0.81 | SCD (0.64) | SCDSMN1; SMN2MAPK1PDE5AHDAC6 | |
| SCHEMBL3095245 | 0.81 | MAPT (0.44) | SCDSMN1; SMN2MAPK1PDE5AHDAC6 | |
| SCHEMBL2314504 | 0.78 | SCD (0.64) | SCDSMN1; SMN2MAPK1HDAC6HDAC3 | |
| SCHEMBL2314537 | 0.78 | SCD (1.00) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1990338-B1 | Biphenylcyclopropylamides as p-38 Kinase inhibitors | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100234404-A1 | P-38 Kinase Inhibitors | LANG HENGYUAN | 2010-09-16 | — | — | US | disclosed |
| US-20100234404-A1 | P-38 Kinase Inhibitors | LANG HENGYUAN | 2010-09-16 | — | — | US | disclosed |
| US-20100234404-A1 | P-38 Kinase Inhibitors | LANG HENGYUAN | 2010-09-16 | — | — | US | disclosed |
| US-7754726-B2 | Benzamide derivatives as p-38 kinase inhibitors | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-7754726-B2 | Benzamide derivatives as p-38 kinase inhibitors | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-7754726-B2 | Benzamide derivatives as p-38 kinase inhibitors | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-7700622-B2 | p-38 kinase inhibitors | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-7700622-B2 | p-38 kinase inhibitors | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-7700622-B2 | p-38 kinase inhibitors | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| EP-1990338-A2 | Biphenylcyclopropylamides as p-38 Kinase inhibitors | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| EP-1990338-A2 | Biphenylcyclopropylamides as p-38 Kinase inhibitors | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| EP-1687284-B1 | p-38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| US-20070111999-A1 | P-38 kinase inhibitors | TRIAD THERAPEUTICS, INC (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070111999-A1 | P-38 kinase inhibitors | TRIAD THERAPEUTICS, INC (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070111999-A1 | P-38 kinase inhibitors | TRIAD THERAPEUTICS, INC (US) | 2007-05-17 | — | — | US | disclosed |
| EP-1687284-A2 | p-38 KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005012241-A2 | p-38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-02-10 | — | — | WO | disclosed |
| US-20050020590-A1 | P-38 kinase inhibitors | NOVARTIS AG (CH) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111999-A1 | P-38 kinase inhibitors | MAPK8, MAP3K8, MAPK1 | SCD 3468/4885SMN1; SMN2 718/4885MAPK1 3/4885 |
| US-20050020590-A1 | P-38 kinase inhibitors | MAPK8, MAP3K8, MAPK1 | SCD 3463/4885SMN1; SMN2 561/4885MAPK1 3/4885 |
| US-20100234404-A1 | P-38 Kinase Inhibitors | MAPK8, MAP3K8, MAPK1 | SCD 3468/4885SMN1; SMN2 718/4885MAPK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.